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Summary 
A  splice  variant  of CD44  (CD44v)  originally discovered on metastases  of a  rat  pancreatic 
adenocarcinoma (BSp73ASML) has been shown by transfection to confer metastatic behavior 
to nonmetastatic tumor cells (Gfinthert U., M.  Hofmann, W.  Rudy, S.  Reber, M. Z611er, I. 
Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. Cell. 65:13). A monoclonal 
antibody (mAb),  1.1ASML,  to the metastasis-specific  domain of the CD44v molecule retards 
growth of lymph node and lung metastases of the metastatic tumor line BSp73ASML, and can 
efficiently prevent formation of metastases by the transfected line. The antibody is only effective 
when given before lymph node colonization. Anti-CD44v does not downregulate the expression 
of CD44v, and prevention of metastatic growth by antioCD44v is not due to activation of any 
kind of immune defense. We suggest that the mAb interferes with proliferation of metastasizing 
tumor cells in the draining lymph node, most probably by blocking a ligand interaction. The 
interference with metastatic spread will greatly facilitate the exploration of the function of CD44v 
and, in particular,  may also open new strategies for the therapy of human metastases. 
C 
D44 is an integral membrane glycoprotein (1-7), origi- 
nally described as a homing receptor of lymphocytes 
(8-17). Beside the involvement of CD44 in adhesion of lym- 
phocytes to specialized endothelial cells, CD44 is known to 
bind to hyaluronate and probably also to collagen (7, 18-30), 
suggesting roles in the interaction between cells and extracel- 
lular matrix. Moreover, several variants of CD44 with addi- 
tional extracellular domains have been detected in a variety 
of tissues  and frequently on tumor cells (1, 31-40). 
The fact that metastatic spread involves interaction between 
tumor cells and extracellular matrix as well as between tumor 
cells and endothelial cells has led to the hypothesis that espe- 
cially the variant forms of CD44 may be involved in the pro- 
cess of metastatic spread (32, 35). Starting from a metastasis- 
specific mAb (1.1ASML) (41) that has been raised against the 
highly  metastatic  pancreatic  adenomcarcinoma line  BSp- 
73ASML  (42),  we have cloned a  splice  variant  of CD44 
(CD44v) 1 (35).  The splice  variant carries an expanded ex- 
tracellular domain. Overexpression of this variant in any one 
of several  nonmetastatizing  tumor  cell  lines  confers  full 
metastatic behavior to these cells (35,  42a). 
l Abbreviations used in this paper: CD44s,  standard CD44; CD44v,  splice 
variant of CD44. 
We  now  report  on  the  specific  interference  of mAb 
1.1ASML with metastasis formation. Intravenous injections 
of 1.LASML inhibited or prevented the colonization of lymph 
nodes and lung. No evidence for an antibody-mediated im- 
mune attack could be detected. Furthermore, 1.1ASML did 
not interfere with surface expression of CD44v. The data sup- 
port the view that CD44v catalyzes embedding/outgrowth 
of tumor cells in the draining lymph nodes. 
Materials  and Methods 
Rats and Tumor Lines.  BDX and DA rats were obtained from 
Charles River (Sulzfeld, Germany). Rats were kept under specific 
pathogen-free conditions and were used for experiments at the age 
of 8-12 wk. BSp73AS (AS) and BSp73ASML (ASML) are the non- 
metastasizing and metastasizing sublines, respectively,  of a sponta- 
neous pancreatic adenocarcinoma of the BDX rat strain (42). Both 
lines were cloned and maintained in vivo by subcutaneous passages. 
BSp73ASpSV14 (AS-14) cells were derived from AS cells after trans- 
fection with CD44v cDNA (pMetal) (35). BSp73ASpSVneo  (AS-20) 
and BSp73ASpSVCD44 (AS-44) were derived from transfections 
with pSVneo and standard CD44 (CD44s) cDNA, respectively  (35; 
M. Hofmann et al., manuscript in preparation). Tumor lines were 
grown in vitro as monolayers in RPMI 1640 supplemented with 
antibiotics, t-glutamine, and 8% FCS (RPMI-s). The transfected 
lines were intermittently passaged  in RPMI-s containing 300 #g/ml 
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and split. As revealed  by fluorescence-activated cell scanning (Coulter 
EPICS; Coulter Electronics GmbH), ASML cells express CD44v 
(staining with 1.1ASML), whereas AS and AS-44 cells express ex- 
clusively CD44s (staining with Ox49 and OxS0) (both mAbs kindly 
provided by A. P. Williams, Institute of Pathology, University of 
Oxford), with AS-44 cells displaying a significantly higher amount 
of CD44s on the surface than AS cells (our unpublished results). 
AS-14 cells express CD44s and CD44v, the latter at a density of 
~75%  in comparison with ASML cells (42b). 
Antibodies.  The mAb 1.1ASML (mouse IgG1) recognizes an 
epitope on exon v6 (43), which was originally designated as do- 
main III of CD44v (35, 41). mAbs Ox49 (mouse IgG2a) and Ox50 
(mouse IgG1) recognize epitopes on both CD44s and CD44v; the 
epitopes of both mAbs have not been mapped, but binding of 
1.1ASML, Ox49, and Ox50 is not competitive, indicating that the 
two epitopes of CD44s and the one epitope of CD44v are not in 
close proximity (42b). mAb 4.4ASML (mouse IgG1) has been de- 
rived from the same fusion as mAb 1.1ASML and recognizes an 
epitope expressed only on the metastatic subline  of the rat pan- 
creatic adenocarcinoma (41). mAb 3-9 (mouse IgG1) is an antigal- 
lium chelate antibody (44), used as an isotype-matched control for 
1.1ASML. The mAbs 1.1ASML, 4.4ASML, and 3-9 were derived 
from culture supematants and were purified by protein A-Sepharose 
chromatography, collecting the fraction eluted at pH 6.0 (45). Ox49 
and Ox50 were used as ascitic fluid. DA anti-BDX serum was de- 
rived by repeated subcutaneous and intramuscular injections of BDX 
lymphocytes in adjuvant. The serum was purified by ammonium 
sulfate  precipitation.  Secondary  antibodies,  FITC-labeled  goat 
anti-mouse IgG1 and IgG2a, were obtained from Southern Biotech- 
nology Associates  (Birmingham, AL). 
Metastasis Assay.  Tissue culture-derived tumor cells were in- 
jected intrafootpad at a dose of 5  x  105/50 #1, if not stated other- 
wise.  Where indicated, the tumor and the draining lymph node 
were excised by amputation in the knee at day 7 (ASML) or 10 
(AS-14)  after tumor cell  application.  Rats  were controlled for 
metastatic tumor growth by measuring draining lymph node di- 
ameter. Rats were killed upon reaching a moribund state, which 
was defined by weight loss (>30%), rigidity of the thorax, short- 
ness of breath, anemia as judged by paleness of the eyes, and a mean 
diameter of >2 cm of palpable lymph node metastases.  Draining 
lymph nodes were weighed and lung colonies were counted. When 
rats  were treated with  mAbs  they received  200/~g  1.1ASML, 
4.4ASML,  or 3-9,  respectively,  twice per week,  intravenously, 
starting on the day of tumor cell inoculation. In one experiment, 
mAb treatment was started after excision of the primary tumor. 
Differences  in lymph node and lung colonization depending on 
mAb treatment were assessed using a paired student's t test. 
Histology.  Metastatic lymph nodes and lungs were fixed with 
4% formalin, cut into 5-#m slices, and stained with hematoxilin- 
eosin. For immunohistology tissue was fixed in liquid nitrogen- 
chilled  ethalan,  cut,  and  stained  with  1.1ASML.  FITC-labeled 
anti-mouse IgG1 was used as second antibody. For quantitative 
immunofluorescence, metastatic cells were separated from remaining 
lymphocytes by a discontinuous Percoll gradient centrifugation (46, 
47), collecting tumor cells from the interface at density (o) 1.077. 
Cells were stained  with 1.1ASML and FITC-labeled anti-mouse 
IgG1;  intensity  was  quantified  with  a  Coulter  EPICS  Profile 
(Coulter Electronics GmbH). 
Soft Agar Colony Assay.  Outgrowth of metastasizing tumor 
cells in draining lymph nodes was estimated by meshing draining 
lymph nodes through fine gauze and dispersing the cell suspension 
in soft agar (0.3%), which was layered on top of a 0.5% agar un- 
dedayer. Hates were incubated at 37~  for 1-2 wk. The number 
of colonies was counted and the size of the colonies was estimated 
using a plaque counter apparatus (Optilux, Quebec). 
Effector Cells and Cytotoxicity Assays.  Spleen, lymph node, and 
peritoneal exudate cells were collected as described (48). If required, 
lymph node cells were separated from tumor cells by Percoll gra- 
dient centrifugation, collecting T cells from the interface ofo 1.210. 
NK cell activity was determined with spleen cells of o 1.077 (49). 
Cytotoxic potential of peritoneal macrophages (M#) was evalu- 
ated as described elsewhere (50). T cells from BDX rats or from 
DA rats, which had received two intravenous injections of irradi- 
ated (30 Gy) BDX lymphocytes, were collected from the interface 
of o 1.210 after Percoll gradient centrifugation of lymph node cells. 
Cells were cultured with 106 irradiated (30 Gy) allogeneic  lym- 
phocytes or with irradiated (400 Gy) tumor cells and/or 50 #g 
affinity-purified  mAbs for 7 d at a density of 2  x  107 cells/5 ml 
RPMI-s, supplemented with 10% conditioned medium containing 
IL-2 (51). Bhst cells were collected and purified from debris by FicoU 
gradient centrifugation (52). 
Cytotoxicity assays were set up in triplicates  plating 104 SlCr- 
labeled  target cells (T) per well and adding titrated numbers of 
effector cells (NK/T =  100-12.5:1; M~/T  =  50-6:1; CTL/T = 
20-2:1) in a total volume of 200 #1 RPMI-s.  For determining 
antibody-depeodent ceUular  cytotoxicity (ADCC),  100  #g/ml 
affinity-purified mAbs were added in addition. Complement cyto- 
toxicity was evaluated by adding preabsorbed guinea pig comple- 
ment (1:5 dilution) to SlCr-labeled target cells, which were prein- 
cubated  with  affinity-purified  mAb.  Comphment  assays were 
terminated after 2 h, NK and CTL assays after 6 h, and M~ assays 
after 12 h. Spontaneous release was in the range of 2-7% (comple- 
ment assay), 10-18% (NK and CTL assay), and 18-25% (M~ assay). 
Specific release was calculated by the formula: percent cytotoxicity 
=  100x  [(counts test well -  counts medium control)/(total counts 
-  counts medium control)]. Spedfic cytotoxidty values >5% were 
statistically significant (student's t test). Differences in cytotoxicity 
values depending on mAb treatment were assessed using a paired 
student's t test. 
In Vivo Evaluation of  lmraune Effector Mechanisms.  The presence 
or absence of tumor-specific and/or mAb 1.1ASML-specific effector 
T cells was evaluated upon transfer of lymph node cells from rats 
that were untreated, or remained free of metastases after they had 
received 5  x  10  s AS-14 cells, intrafootpad, and multiple injections 
of 1.1ASML, intravenously.  Irradiated recipient rats (8.5 Gy) re- 
ceived  5  x  10  s BSp73ASML  cells, intrafootpad, concomitantly 
with an intravenous injection of 5  x  107 lymph node cells. The 
diameter of draining lymph nodes was determined every 3 d. Animals 
were killed after 28 d, draining lymph nodes were weighed, and 
lung colonies  were counted. 
ADCC-like mechanisms functioning in vivo were estimated by 
application of 5  x  104 mI-UDK-labeled (3 #Ci/culture for 72 h) 
tumor cells, intrafootpad, together or without intravenous injec- 
tions of mAb. Tumor cell decay was determined by recording re- 
maining radioactivity in a whole body counter, as described previ- 
ously (53). Rats were killed after 10 days, the draining lymph nodes 
were excised, and the number of tumor cells was determined by 
cloning in soft agar,  as described  above. 
Results 
A  Variant Form of CD44 Containing Additional Exons,  but 
Not CD44s, Confers Metastatic Potential.  The system used to 
investigate the function of CD44v in metastasis  formation 
is based on cell lines derived from the pancreatic carcinoma 
444  Variant  CD44 in Metastasis Formation Figure 1.  Metastatic progression of CD44v-positive  tumor lines. (A and B) Expression of CD44v initiates metastatic progression.  (A) BDX rats 
received 5  x  l0  s tumor cells, intrafootpad.  The tumor and the draining popliteal lymph node were excised 10 d later by amputation in the knee. 
Rats were killed reaching a moribund state. Rats that had received ASML (CD44v  +) and AS-14 (CD44v*  by transfection) became moribund between 
30 and 60 d after tumor cell inoculation. Rats that had received AS (CD44v-), AS-20 (CD44v-, transfected with pSVneo), and AS-44 (CD44v-, 
overexpression of CD44s by transftction)  remained tumor free. (B) BDX rats received, intrafootpad,  5  x  10  s AS-14 tumor cells that had been derived 
from either a primary nodule, or a lymph node or a lung metastasis. Rats were amputated and killed at a moribund state. (C and D) Metastasis formation 
in the lung. BDX rats received 5  x  10  s ASML (C) or AS-14 cells (D),  intrafootpad,  and were killed 35 d later. In the lung of ASMbbearing rats 
a diffuse infiltration of alveolar walls by tumor cells was noted.  AS-14 cells settled in nodular form in the lung; a single nodule is shown,  x40. 
BSp73 (42). Animals that have been injected with the non- 
metastatic cell line BSp73AS (AS) develop only a local tumor 
and remain healthy after excision of the local tumor. The highly 
metastatic cell line BSp73ASML (ASML)  rapidly colonizes 
lymph nodes and lung and all animals  become moribund 
within 60 d  after  intrafootpad application. The metastatic 
spread is complete at day 10, after which time excision of 
the local tumor together with the draining popliteal lymph 
node is inef:ficient.  AS cells transfected with CD44v, as demon- 
strated for clone AS-14,  are  as metastatic as ASML cells, 
whereas G418-resistant  control transfectants (done AS-20) 
and, most importantly, transfectants with CD44s (done AS- 
44)  are nonmetastatic (Fig.  1 A). 
To assure that it is solely expression of CD44v (and not 
an additionally property selected  in vivo) that confers metastatic 
behavior to transfected  AS cells, AS-14 cells were reisolated 
from local  tumors as well as from lymph node and lung 
metastases. According to fluorescence  analysis, AS-14 cells from 
all three sources expressed equivalent levels of CD44v (data 
not shown). Upon intrafootpad injection of the different reiso- 
lates, all animals developed lymph node and lung metastases 
with the same kinetics as the original AS-14 cell clone (Fig. 
1 B). 
Both, ASML and AS-14 cells metastasize via the lymphatic 
system to the lung. Yet, there are discrete differences between 
these lines, suggesting that CD44v cDNA does not confer 
all properties by which ASML cells differ from AS cells. (a) 
ASML cells do not form a local tumor in the footpad, the 
site of injection while after injection of AS-14 cells a locally 
growing encapsulated tumor is observed in some but not all 
rats.  (b) Although the time course of lymph node and lung 
involvement is similar for ASML and AS-14 cells (data not 
shown), the morphology of the metastases is different. ASML 
cells diffusely infiltrate lymph nodes and lung giving rise to 
innumerable miliary nodules (Fig.  1 C), while with AS-14 
cells the nodular form of metastatic setdement predominates 
(Fig.  1 D). 
An Anti-CD44v mAl~ 1.1ASML,  Inhibits Metastasis Forma- 
tion.  The causal involvement of CD44v in metastatic be- 
havior made us attempt to interfere with metastatic spread 
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Figure 2.  Retardation  and prevention of metastasis formation.  BDX 
rats received 5  x  10  s ASML (.4) or AS-14 cells (B), intr~'ootpad,  and, 
where indicated, 200 ~g 1.1ASML, intravenously, twice per week, starting 
at the day of tumor cell inoculation. The time for reaching a moribund 
state of six ASMbbearing rats per group and of 25 AS-14-bearing rats 
per group is shown. 
by a mAb. Rats received a tumor dose of >10 x  TDl00 (in- 
trafootpad)  together with the anti-CD44v mAb 1.1ASML 
(intravenously).  Thereafter, mAb application (intravenous) 
was repeated twice per week. The effect of 1.1ASML was 
clearcut. The survival time of animals carrying ASML could 
be doubled,  although the local depot of tumor cells at the 
site of injection was not excised. In animals injected with 
AS-14, metastasis formation could be completely prevented 
in 17 of 25 rats (Fig. 2). In this particular experiment, only 
two rats of the control group and two rats of the 1.1ASML- 
treated group developed a local tumor, which was excised 
when reaching a mean diameter of 0.3 cm. In the remaining 
rats no tumor developed at the injection site and, hence, the 
limb  was  not  resected.  After discontinuing injections  of 
1.1ASML at  140 d, animals remained healthy. When they 
were killed at day 240, histological examination  of lymph 
nodes and lung did not reveal any sign of metastatic tumor 
cell growth (data not shown). 
Complete inhibition of metastatic growth of AS-14 was 
Table  1.  Tumor  Takes under 1.1ASML  Treatment 
Metastatic growth (moribund state) 
Line  Dose  Control mAb  mAb 1.1ASML 
ASML 
AS-14 
￿  ~  d  d 
500  5/5  (39)  5/5 (61) 
170  5/5  (42)  5/5 (86) 
60  5/5 (56)  5/5 (94) 
40  4/5  (66)  2/5 (144) 
20  3/5  (75)  0/5 (163) 
500  5/5  (54)  3/5  (66) 
170  5/5  (58)  2/5  (79) 
60  5/5 (66)  0/5 (-) 
40  5/5  (78)  0/5  (-) 
20  3/5 (98)  0/5 (-) 
Rats received either 200 #g 3-9 (control mAb) or 1.1ASML, intravenous- 
ly, twice per week. 
obtained at a tumor dose of 1.5  x  TD100 (6  x  104 tumor 
ceils).  In  ASMbbearing rats  the  survival  time could be 
prolonged by lowering the dose of tumor cells, but only at 
1  x  TD100, 1.1ASML prevented metastasis formation (Table 
1). The difference between the metastatic BSp73ASML line 
and the transfected line is an interesting  feature: although 
CD44v  expression  suffices to  confer metastatic  behavior, 
ASML cells apparently  have more complex properties. 
The delay in metastasis formation by 1.1ASML treatment 
is reflected at the level of lymph node enlargement and of 
the number of lung colonies. When ASML cells reach the 
draining lymph node, a rapid onset of growth is observed 
within 20-30 d after injection. In 1.1ASMbtreated animals, 
the enlargement of lymph nodes was ddayed by 15-30 d (Fig. 
3 A). After injection of AS-14, a longer time span of 30-55  d 
was required for outgrowth of metastases in the draining 
lymph node. In >80% of animals, the formation of lymph 
node metastases could be completely obliterated by 1.1ASML 
(Fig. 3 B). The failure of outgrowth of tumor cells in draining 
lymph nodes was confirmed by soft agar cloning of tumor 
cells out of draining lymph node suspensions. In the case of 
1.1ASML-treated, ASML-bearing rats,  the development  of 
clones was ddayed and remained reduced as compared with 
the number of  clones in untreated rats (Fig. 3 C). In 1.1ASMI~ 
treated,  AS-14-bearing rats, only occasionally were one to 
two clones obtained from draining lymph nodes (Fig. 3 D). 
At 28 d after inoculation ASML cells showed massive set- 
tlement in the lung of untreated or mock-treated (mAb 3-9; 
data not shown) rats. In 1.1ASMbtreated rats, however, the 
number of lung nodules were reduced to one to eight (Table 
2). In AS-14-bearing rats, the development of  lung metastases 
under the treatment with 1.1ASML was (if occurring at a11) 
markedly reduced as judged from the very low number of 
lung nodules  (Table 2). 
446  Variant CD44 in Metastasis Formation poplitasl  lymph node diameter  (cm) 
4- 
8- 
0 
s 
li 
￿9  -.-......,..,...,.  'i I  .+'"  ;[ 
................................  iii'/  ....................  i 
I:  .....................  i  ................................  .... 
10  24  82  40  48  66  04 
Days after  AaML  cell Implantation 
10 
8 
8 
4 
2 
0 
xlOexp3 tumor cell colonies  (8oft soar) 
day 11 
day ~6 
day 19 
B  day Z8 
C 
*I.IAaML  *I.IAaML 
popllteal LN  paramortic LN 
Draining lymph node (AaML-bearlng  rats) 
B 
poplltael lymph node dieuneter  (cm) 
i  | i  1 
s-  ....  A8-14  ,  ,II  .....................................  ~ ..................  i ............................ 
t" 
xlOexp3  tumor cell colonies  (soft agar) 
12 
lO 
6 
dsy18 
dILy e8 
flt~  day m;' 
I  dlly 81 
D 
*I.IASML 
popllteld LN  pamortir  LN 
Draining lymph node (A8-14  bearing rats) 
O; 
16  24  82  40  48  56  64  72 
Days  after  ,6,8-14 cell implantetion 
Figure 3.  Retardation of metastatic lymph node colonization by anti*CD44v. (A and B) The mean diameter and standard deviations of the popliteal 
lymph nodes of 1.1ASMl.-treated and untreated ASML- and AS-14-bearing rats (six/group)  are shown. It should be noted that with five of six mAb- 
treated, AS-14-bear/ng rats, the popliteal lymph node did not become palpable. (C and I)) For the quantitation of metastasizing cells, draining lymph 
nodes of ASMb and AS-14-bearing rats, which were untreated or treated with 1.1ASML, were excised  between 11 and 31 d after intrafootpad inoculation 
of tumor cells. Lymph nodes were meshed, plated in soft agar, and the number of tumor cell colonies was counted after 10 d of culture. Mean values 
of three to five lymph nodes per group are shown. 
Finally, it should be noted that lymph node and lung coloni- 
zation was retarded after only one injection of 1.1ASML. Yet, 
retardation of metastatic growth was vanishing at around 3 
wk after cessation of 1.1ASML treatment. In addition, the 
effect of 1.1ASML on metastasis formation was highly specific 
for epitopes  on  CD44v.  As  a control antibody we used 
4.4ASML. This antibody is of the same isotype as 1.1ASML, 
but binds to a different molecule on ASML (not on AS-14) 
cells. The epitope density for 4.4ASML is in the same range 
as CD44v expression (our unpublished finding). When ASMb 
bearing rats received intravenous injections of 4.4ASML, de- 
velopment of metastases in lymph nodes and lung was not 
retarded at all (Fig. 4). 
The antibody experiments now permit us to explore the 
mechanism of antibody interference. The following possibil- 
ities will be considered.  First,  1.1ASML could function as 
a trigger for immune effector mechanisms. Second, the anti- 
body may interfere with the expression  of  CD44v, i.e., binding 
of 1.LASML could result in downreguhtion of CD44v. Third, 
occupancy by the antibody inhibits the function of CD44v, 
e.g.,  a ligand interaction required for embedding of meta- 
stasizing tumor cells. 
Reduction of  Metastasis Formation by 1.1ASML Is Not Medi- 
ated by Immune Mechanisms.  As described elsewhere (54), 
when using a protocol of preimmunization with a mAb ex- 
plicitly adapted to initiate a cascade of immune responses, 
the appearance of antiidiotypic antibodies  in response  to 
1.1ASML did not at all support a reduction of metastatic 
spread. Rather, an acceleration of metastatic spread was ob- 
served. In view of this finding,  it was considered unlikely 
that immune mechanisms would account for the retardation 
of metastatic spread under 1.1ASML treatment. Since, how- 
ever, the protocol of 1.1ASML application used here differed 
decisively from that described previously, the following im- 
447  Seiter etal. Table  2.  Reduction of the Number of Lung Colonies under 1.1ASML  Treatment 
Lung colonies 
Treatment*  Day#  No.  Diameter 
cm 
ASML  28  >1,000  0.1 
ASML  +  1.1ASML  28  1-8s  0.1 
ASML  50  >2,000  0.1 
ASML  +  1.1ASML  100  100-200s  0.1 
AS-14  50  30-80  0.3-1.0 
AS-14  +  1.1ASML  100  0-8s  0.8-1.0 
* BDX rats (seven per group) received 5  x  10  s ASML or AS-14 cells, intrafootpad; where indicated, rats were treated with  200/~g  1.1ASML, 
intravenously, twice per week. 
t Time after injection of tumor cells. 
$ Significant differences ~  <  0.05) in the numbers of lung colonies in untreated vs 1.1ASML-treated rats. 
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(a) The antibody is not cytotoxic by itself.  When ASML 
and AS-14 cells were cultured for 4-96 h  in the absence of 
mAb or presence of  control mAbs 3-9, OxS0 (anti-CD44s), 
or  1.1ASML,  thymidine incorporation was not reduced at 
all in cultures containing 1.1ASML as compared to cultures 
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Figure 4.  mAb-induced retardation of metastasis formation requires 
binding to CD44v. Rats (five/group) received 5  x  10  s ASML cells in- 
trafootpad, concomitantly with 200/zg 1.1ASML  or 4.4ASML, intrave- 
nously. Where indicated, mAb application was repeated 3 and 6 d later. 
The mean diameter and standard deviations  of  the draining popliteal lymph 
nodes (/1) and the number of lung metastases (B) are shown. 
Figure 5.  mAb 1.1ASML is neither cytotoxic nor cytopathic. ASML 
cells (800) were seeded in soft agar containing no mAb (A), 10 Izg/ml 
3-9 (B), OxS0 (C), and 1.1ASML  (D), respectively. Plates were incubated 
for 7 d at 37~  5% CO2 in air. Thereafter colonies were counted: 144 
(A), 163 (B), 152 (C), 738 (19). 
448  Variant  CD44 in Metastasis Formation Table  3.  Antibody- and Complement-mediated Lysis 
Percent 
cytotoxicity 
Target  Antibody*  No C*  C* 
ASML 
AS-14 
-  3.2  5.7 
3-9  2.2  5.3 
1.1ASML  1.9  7.4 
Anti-BDX  2.3  21.2S 
-  4.1  8.1 
3-9  4.1  7.9 
1.1ASML  2.8  9.6 
Anti-BDX  3.4  78.3s 
* Target cells were preincubated with the mAb 3-9 (control IgG1) or 
1.1ASML (IgG1), or with DA anti-BDX IgG at a concentration of 10 
/~g/ml. 
* Guinea pig serum as source of complement, 1:5 diluted in HBSS. 
S A significant increase ~ < 0.05) in cytotoxicity in the presence of an- 
tibody. 
where 3-9, Ox50, or no antibody was added. Interestingly 
enough,  addition  of 1.1ASML,  but  not  of 3-9  or Ox50, 
reproducibly enhanced the cloning efficiency of ASML (and 
AS-14; data not shown) cells (Fig.  5). Thus, at least in vitro, 
any cytopathic effect of 1.1ASML could be excluded. 
In addition,  neither in the absence nor in the presence of 
complement was a considerable increase in the lysis of 51Cr- 
labeled target cells observed by addition of 1.1ASML, although 
tumor cells were lysed in the presence of complement  and 
an aUoantiserum directed against the MHC haplotype of the 
tumor  (Table  3). 
(b) Antibody-dependent cellular cytotoxicity is a priori un- 
likely because of the IgG1 isotype of 1.1ASML. With perito- 
neal macrophages and NK-enriched spleen ceils, the cytotoxic 
potential of the effector cells was only insignificantly increased 
for 1.1ASML-loaded vs. unloaded tumor cells.  This applies 
to ASML as well as AS-14 target ceils, with lysis in the pres- 
ence of 1.1ASML being augmented by only 2-10%  (Table 
4). Antibody-dependent cytotoxicity by unseparated spleen 
cells, including granulocytes, and by LAK cells could not be 
detected at all (data not shown). It should, however, be noted 
that AS-14 cells are highly susceptible to lysis by NK ceUs, 
LAK cells (data not  shown),  and macrophages.  At a 50:1 
ratio of E/T cells,  36.4 and 49.6%,  respectively, of AS-14 
cells  are lysed, while ASML cells  are rather  resistant  (NK 
lysis, 2.4%; and M~ lysis, 16.3%). Furthermore, in the pres- 
ence of an alloantiserum AS-14 cells were lysed at a consider- 
ably higher degree than ASML cells. However, as will be dis- 
cussed below, there is no evidence that the high susceptibility 
of AS-14 cells  for immune  effector mechanisms  is relevant 
for the more efficient eradication by 1.1ASML treatment of 
AS-14 than  of ASML cells. 
(c) Finally, the possibility had to be taken into account that 
mouse Ig-specific cytotoxic T cells may take part in the preven- 
tion of metastatic spread in 1.1ASML-treated rats.  Although 
Ig-specific helper  T  cells  were present  after application  of 
1.1ASML in adjuvant  (54),  neither  Ig-specific helper  (data 
not shown) nor cytotoxic T cells could be detected after in- 
travenous application of 1.1ASML. After in vitro restimula- 
tion with tumor calls plus 1.1ASML, T cells from draining 
lymph nodes of tumor-bearing  rats did not reveal  any sig- 
nificant degree of cytotoxic potential for 1.1ASML-coated or 
noncoated target cells. This was irrespective of whether the 
T cells were derived from 1.1ASML-treated or untreated rats. 
Since AS-14 cells and,  to a lower degree, ASML cells were 
lysed by cytotoxic T cells from DA rats,  the experiment ex- 
cludes activation of tumor call-specific as well as Ig-specific 
cytotoxic T  cells  (Table  5). 
The idea that retardation/prevention  of metastasis forma- 
Table  4.  Antibody-dependent  Cellular Cytotoxicity 
Percent  cytotoxicity 
ASML  +  AS-14  + 
Effector 
cells"  E/T  None  1.1ASML  Anti-BDX  None  1.1ASML  Anti-BDX 
NK 
Mq~ 
100:1  3.8 
50:1  2.4 
25:1  1.1 
50:1  16.3 
25.1  10.2 
12.1  6.5 
5.4  19.7'  50.6  60.5  78.5* 
4.1  13.2*  36.4  44.1  59.3* 
2.3  7.9*  28.2  34.3  42.2* 
23.0  37.8*  49.6  53.1  85.6* 
14.6  23. It  38.3  42.1  63.7* 
11.2  19.4'  24.2  31.7  48.5* 
* NK, spleen cells, Percoll fraction of cr 1.077; MO, adherent peritoneal cells. 
* A significant increase (p <0.05) in cytotoxicity in the presence of antibody. 
449  Seiter et al. Table  5.  Ig-specific C?totoxic T  Cells 
Lymphocyte 
donor  Stimulus*  ASML 
Percent  cytotoxicity* 
ASML  +  AS-14  + 
1.1ASML  AS-14  1.1ASML 
BDX  ASML 
BDX  ASML  +  1.1ASML 
DA  BDX lymphocytes 
BDX  AS-14 
BDX  AS-14  +  1.1ASML 
DA  BDX lymphocytes 
6.1 
5.3 
23.1 
3.2 
5.2 
14.0  12.9 
14.1  11.2 
68.5 
* Cytotoxicity values  are  shown for a ratio of E/T cells of 10:1. 
* BDX lymph node cells were derived from tumor-bearing rats that had or had not received  1.1ASML treatment. They were restimulated in vitro 
under the same conditions. DA lymph node cells were derived from DA rats that had received  two injections of irradiated BDX lymphocytes and 
were restimulated in vitro with BDX lymphocytes. 
tion by 1.1ASML is not based on immune effector mecha- 
nisms was further supported by the following in vivo ex- 
periments.  The  possibility  of an  ADCC-like  mechanism 
functioning in vivo was evaluated by simultaneous injections 
of nsI-UDK-labeled ASML cells (intrafoodpad)  and 1.1ASML 
or 3-9 (intravenous) in nonirradiated and sublethaUy irradi- 
ated rats. The survival rate of tumor cells was recorded during 
the following 48-240 h by whole body counting. Throughout 
the first 48 h, the tumor cell decay (ASML and AS-14) was 
totally independent of 1.1ASML application. This accounted 
for nonirradiated as well as irradiated rats (Fig.  6 A). Only 
thereafter was tumor cell decay slightly accelerated in 1.1ASML- 
as compared with mock-treated rats,  the accelerated decay 
again being independent of immunocompetence of the host 
(Fig. 6 B). Thus, it appears unlikely that retardation/preven- 
tion of metastases formation under 1.1ASML treatment re- 
lies on an ADCC-like mechanism. 
In conformity with the in vitro results, there was no evi- 
dence for a tumor-specific and/or 1.1ASMbmediated T cell 
response in vivo. Lymph node cells from rats, which had re- 
ceived AS-14 cells and 1.1ASML treatment and remained free 
of metastases, were transferred into irradiated rats that re- 
ceived concomitantly 3  x  105 AS-14 cells.  Metastases for- 
mation was not at all retarded or inhibited in comparison 
with rats that had received lymph node cells from untreated 
rats  (data  not  shown).  We  conclude  that  prevention  of 
metastatic spread by 1.1ASML is not due to activation of any 
kind of immune defense mechanisms. 
Exclusion of 1.1ASML-mediated Modulation of Expression of 
CD44v.  Since a defined threshold level of surface expres- 
sion is probably essential to initiate metastatic spread of non- 
metastasizing cells transfeeted with CD44v cDNA (35; Hof- 
mann et al., manuscript in preparation), we now investigated 
whether anti-CD44v treatment results in downregulation of 
CD44v expression. In fact, this was not the case. Fluores- 
cence staining of ASML and AS-14 cells, which were cul- 
tured in the presence or absence of 1.1ASML for 1 wk, re- 
vealed no decrease in the intensity of staining with 1.1ASML 
(Fig.  7, A  and B). Also,  in vivo, expression of CD44v was 
not downmodulated under 1.1ASML treatment (shown for 
ASML cells isolated from draining lymph nodes; Fig. 7 C). 
Accordingly, AS-14 lung nodules of 1.1ASMIrtreated and un- 
treated rats were stained with 1.1ASML  at comparable in- 
tensity (data not shown). 
Expression of CD44v Is Required during Embedding and/or 
Outgrowth of  Metastatic Cells in Lymph Nodes.  A further hint 
at the possible function of CD44v during metastatic spread 
was derived from experiments in which the application of 
anti-CD44v was ddayed. Starting 1.1ASML treatment at the 
time of tumor cell inoculation prevented metastasis forma- 
tion and/or prolonged the survival time. Even after a single 
injection of 1.1ASML,  formation of metastasis was delayed. 
However, 1.1ASML  was inefficient when injected 10-14 d 
after tumor cell inoculation, irrespective of excision of the 
local tumor and the draining popliteal lymph node (Table 6). 
The finding that expression of CD44v is required early 
during metastasis formation was further supported by exci- 
sion of the popliteal lymph node after intrafootpad applica- 
tion of 5  x  106 ~2sI-UDR-labeled  tumor cells into irradi- 
ated rats (8.5 Gy) and determining the level of radioactivity 
in parallel  with the number of tumor cell colonies in soft 
agar.  A peak of radioactivity was detected 4 d after tumor 
cell inoculation. This was independent of the concomitant 
application  of 3-9  or  1.1ASML.  Thereafter,  radioactivity 
declined more rapidly in the draining lymph node of 1.1ASML- 
as compared with mock-treated rats, indicating a 1.1ASMb 
dependent, decreased survival rate of tumor cells in the draining 
lymph node. Lymph nodes excised at 10 d after tumor cell 
inoculation were dispersed and cloned in soft agar.  In the 
lymph node of 3-9-treated rats, >2,000 ASML and >1,000 
AS-14 colonies were detected. In 1.1ASMbtreated rats,  51 
ASML and 19 AS-14 colonies appeared. This indicates that 
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Table  6.  Delayed  Injection of I.1ASML Does Not Inhibit Metastatic 
Spread 
1.1ASML* 
treatment  Excision 
Line*  (day)  (day)  Tumor takes  Moribund state 
ASML 
AS-14 
d 
-  -  5/5  55 
-  10  5/5  57 
0  -  5/5  95 
0  10  2/5  120 
10  -  5/5  59 
10  10  5/5  67 
-  -  5/5  59 
-  14  5/5  63 
0  -  2/5  109 
0  14  0/5  -s 
14  -  5/5  68 
14  14  5/5  95 
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Figure 6.  In vivo elimination of 12SI-DUR.-labeled  ASML cells in im- 
munocompromised rats. Nonirradiated and irradiated (8.5 Gy) BDX rats 
received 5  x  106 12sI-UDR.-labeled ASML cells, intrafootpad, together 
with 200/~g 3-9 or 1.1ASML, intravenously. Antibody application was 
repeated every  3 d. Mean percent of retention of radioactivity  (whole body 
counts, five rats/group) was determined after 4-240 h. 
* 5  x  10s ASML or AS-14 cells, intrafootpad. 
t 200/~g 1.1ASML, intravenously, twice per week, starting at the in- 
dicated day after tumor cell application. 
S R.ats were killed at day 150 and were tumor free. 
tumor cells had started to divide in mock-treated, but not 
in ASML-treated rats  (Fig.  8). Thus,  expression of CD44v 
is required early in metastasis formation. In particular, CD44v 
appears  to be important  for settlement  and outgrowth  of 
tumor cells in  the lymph  node. 
Discussion 
Overexpression of CD44v is sufficient to confer metastatic 
potential to nonmetastasizing tumor cells (35). Since several 
tumor lines, irrespective of their histology, acquired metastatic 
potential with CD44v expression (M. Hofman et al., manu- 
script in preparation), it appears that CD44v implements a 
common limiting function for tumor cell progression.  So 
far, the smallest version of CD44v conferring metastatic prop- 
erties carries only 85 amino acids (including the epitope for 
1.1ASML) of extra sequence in the variant part of the mole- 
cule (42a). We have shown now that mAb 1.1ASML binding 
within  this variant part  of CD44  interferes strongly with 
the outgrowth of metastases.  The following features could 
be instructive as to the basic function of the CD44v molecule. 
(a) 1.1ASML affects lymphatic spread of both ASML and 
AS-14 cells. Yet, metastasis formation of AS-14 cells is more 
efficiently inhibited.  This indicates  that  ASML  and AS-14 
cells differ in properties not transferred by CD44v. We know 
that ASML and AS cells, AS-14 cells being derived from the 
latter, differ in susceptibility to NK cells and macrophages, 
in the morphology of tumor nodules and in their cytoskeletal 
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Figure 7.  Anti-CD44v does not modulate expression of CD44v. ASML (A) and AS-14 (B) cells were cultured for 1 wk in the absence or presence 
of 10/~g/ml 1.1ASML. (C) ASML cells were derived from the draining lymph node of ASML-bearing untreated and  1.1ASMLtreated  rats.  Tumor 
cells were stained with 1.1ASML as first, and FITC-labeled anti-mouse [gG1 as second, antibody. (Striped) Negative control; (b/a~/e) cultured or grown 
in vivo in the absence of 1.1ASML; (crosshatched) cultured or grown in vivo in the presence of 1.1ASML. 
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Figure 8.  Influence of anti-CD44v on tumor cell decay and prolifera- 
tion in the draining lymph node.  Sublethally  irradiated  (8.5  Gy) BDX 
rats received 5  ￿  10  e t2sI-UDR-labeled  ASML (A) and AS-14 (B) cells, 
structure (42, 47, 55-58). It is plausible that molecular func- 
tions in addition to CD44v influence invasiveness and meta- 
static potential. Obviously, however, CD44v represents a deci- 
sive element in  metastasis  formation of both  ASML and 
AS-14 cells. 
(b) 1.1ASML does not function by implementing immune 
effector cells or by initiating an Ig-specific T  cell response. 
The whole array of antibody-mediated or antibody-induced 
immune defense mechanisms was tested in vitro and/or in 
vivo and found to be inefficient. On the contrary, under in 
vivo conditions, 1.1ASML supports the cloning efficiency of 
tumor cells. In addition, the higher susceptibility of AS-14 
cells for nonadaptive immune effector cells (47) could facili- 
tate tumor cell eradication. Yet, this is not a decisive factor, 
since we observed in sublethaUy irradiated rats,  as well,  a 
blockade of AS-14 outgrowth in the presence of 1.1ASML 
(Fig.  8).  Finally,  1.1ASML  failed  to  mount  an  efficient 
anti-mouse Ig cytotoxic T cell response (59).  This was not 
actually surprising, if one is aware of an important physio- 
logical function of CD44v in lymphocyte activation. During 
the activation process, T cells express CD44v, and activation 
can be inhibited efficiently by anti-CD44v  (43),  i.e.,  anti- 
CD44v  displays immunosuppressive properties. 
intrafootpad,  and every 3 d, 200/zg mAb, intravenously,  starting at the 
time of tumor cell inoculation. The draining and the contralateral popliteal 
lymph nodes of three rats per group were excised at the indicated  time 
points,  and radioactivity was determined  in a gamma counter.  Mean cpm 
of the draining  lymph node minus mean cpm of the contralateral  node 
(12-37 cpm) are shown.  At 10 d after tumor cell application,  the excised 
lymph nodes were meshed and plated in soft agar. The number of colonies 
visible after  7 d of culture is reported. 
452  Variant CD44 in Metastasis Formation (c) 1.1ASML is only efficient when present before the es- 
tablishment of metastatic colonies. In addition,  evaluation 
of remaining radioactivity in the draining lymph node after 
injection  of lasI-UDR-labeled  tumor  cells  indicates  that 
comparable numbers of tumor ceils reach the draining lymph 
node in 1.1ASML- and mock-treated rats. Yet, outgrowth of 
tumor ceils appears to be inhibited. These findings, together 
with the observation that 1.1ASML does not downregulate 
expression of CD44v, provide the basis of our working hy- 
pothesis on the function of CD44v and on the interference 
by 1.1ASML. CD44v is required early in lymphogenic spread. 
The antibody appears to cover efficiently CD44v-positive cells 
during migration and prevents CD44v from passing through 
a decisive interaction with an as yet unknown ligand. Ligand 
binding could be an initial step for signal transduction and/or 
activation of an enzymatic machinery, which allow for selec- 
tive survival and expansion of tumor cells in lymph nodes 
and lung. If this interaction is blocked long enough, the cells 
cannot survive and the animal remains free of metastases. 
Irrespective of the functional definition of CD44v at the 
molecular level, the observation that by an antibody blockade 
metastatic spread can be obliterated has importance in itself. 
Although retardation of metastatic spread by mAbs directed 
against cell surface receptors required for metastatic progres- 
sion has been described in several systems (54, 60-65), preven- 
tion of metastasis formation by a mAb, to our knowledge, 
was observed for the first time. This finding undoubtedly 
is most promising for the development of new therapeutic 
strategies. 
The rat anti-CD44 mAbs Ox49 and Ox50 were kindly provided by A. F. Williams (Institute of Pathology, 
University of Oxford, Oxford, UK). 
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